Nektar Therapeutics (NKTR)
36.50
-0.42
(-1.14%)
USD |
NASDAQ |
Jan 22, 16:00
36.50
0.00 (0.00%)
After-Hours: 16:24
Nektar Therapeutics Cash from Investing (Quarterly): -94.87M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Rigel Pharmaceuticals, Inc. | -33.18M |
| Insmed, Inc. | -762.23M |
| Eli Lilly & Co. | -2.983B |
| Ironwood Pharmaceuticals, Inc. | -0.002M |
| Lyell Immunopharma, Inc. | 3.349M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -48.76M |
| Cash from Financing (Quarterly) | 141.68M |
| Free Cash Flow | -190.35M |
| Free Cash Flow Per Share (Quarterly) | -2.580 |
| Free Cash Flow to Equity (Quarterly) | -39.22M |
| Free Cash Flow to Firm (Quarterly) | -42.83M |
| Free Cash Flow Yield | -8.08% |